What Is BIIB Fair Value?
Biogen (BIIB) fair value estimate using multiple valuation models, updated daily.
As of October 14, 2026, Biogen (BIIB) has a composite fair value estimate of $311.43 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $228.90, suggesting the stock is undervalued by 36.1%.
Data as of October 14, 2026 (today)
Composite Fair Value
Undervalued3 of 4 models$311.43
vs. current price of $228.90(+36.1%)
How Is BIIB Fair Value Calculated?
Four independent models estimate what BIIB is worth. Each uses different inputs and assumptions. The composite blends them by weight.
BIIB Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$451.40
+97.2%Undervalued
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
BIIB Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$189.85
-17.1%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$125.53
-45.2%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $228.90 is 97.2% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.36B | $1.30B |
| Year 2 | $1.46B | $1.33B |
| Year 3 | $1.56B | $1.36B |
| Year 4 | $1.68B | $1.39B |
| Year 5 | $1.80B | $1.42B |
| Year 6 | $1.93B | $1.45B |
| Year 7 | $2.07B | $1.49B |
| Year 8 | $2.21B | $1.52B |
| Year 9 | $2.37B | $1.56B |
| Year 10 | $2.55B | $1.59B |
| Terminal Value | $113.64B | $71.13B |
What Are BIIB's Key Financial Metrics?
Earnings & Growth
Current Price
$228.90
EPS (TTM)
$5.54
Forward P/E
13.8
Profit Margin
8.3%
Cash & Balance Sheet
Free Cash Flow
1.3B
EBITDA
3.4B
Book Value
$127.61
Total Debt
8.4B
What Do Analysts Say About BIIB?
Low
$175.00
Average
$243.98
High
$300.00
Upside
+6.6%
BIIB Fair Value FAQ
What is the fair value of BIIB?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), BIIB's estimated fair value is $311.43. The stock is currently trading at $228.90, which makes it undervalued by our analysis.
How is BIIB's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is BIIB overvalued or undervalued?
Based on our analysis, BIIB is undervalued. The current price of $228.90 is 36.1% below our estimated fair value of $311.43.
What do Wall Street analysts say about BIIB?
32 analysts cover Biogen with a consensus rating of "Buy." The average price target is $243.98, ranging from $175.00 to $300.00. This implies 6.6% upside from the current price.